Interprotein, RaQualia deal

The companies partnered to discover and develop protein-protein interaction inhibitors for undisclosed pain indications. RaQualia will be responsible for discovering candidates, while Interprotein will use its Engine for New Drug Design (INTENDD) technology to perform in silico screening of the inhibitors. RaQualia is eligible for worldwide, exclusive rights of any products resulting from the partnership. Interprotein is eligible for an undisclosed upfront payment, a contingency payment and research milestones. The companies could not be reached for details. ...